FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HCT type: (check all that apply) 

 
 

gfedcb
Autologous

 
 

 
gfedcb

Allogeneic, unrelated

 
 

 
gfedcb

Allogeneic, related

 

Product type: (check all that apply) 

 
 

gfedcb
Bone marrow

 
 

 
gfedcb

PBSC

 
 

 
gfedcb

Single cord blood unit

 
 

 
gfedcb

Multiple cord blood units

 
 

 
gfedcb

Other product

 
 
Specify:    

 
 

Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 
 

Is the second or subsequent transplant for relapse or progression of the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 
 

1  What is the diagnosis?

    
 nmlkji

Multiple myeloma (symptomatic)  

 nmlkji
Plasma cell leukemia (PCL)  

 nmlkji
Solitary plasmacytoma (in absence of bone marrow findings diagnostic for multiple myeloma or PCL)  

 nmlkji
Amyloidosis  

 nmlkji
Osteosclerotic myeloma / POEMS syndrome  

 nmlkji
Light chain deposition disease  

 nmlkji
Other plasma cell disorder (PCD)  

 
 
2  Specify other plasma cell disorder:    

 
 

3  Solitary plasmacytoma was

    
 nmlkji

Extramedullary  
 nmlkji

Bone derived  

 
 
4  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 
 

5  Did the recipient have a preceding or concurrent plasma cell disorder?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 8

  Preceding/Concurrent Disorder (1) Questions: 6 - 8 

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 23



 
 
6  Specify preceding / concurrent disorder

 nmlkji
Multiple myeloma (symptomatic)  

 nmlkji
Smoldering myeloma (asymptomatic)  

 nmlkji
Plasma cell leukemia  

 nmlkji
Solitary plasmacytoma  

 nmlkji
Amyloidosis  

 nmlkji
Osteosclerotic myeloma / POEMS syndrome  

 nmlkji
Light chain deposition disease  

 nmlkji
Monoclonal gammopathy of unknown significance (MGUS)  

 nmlkji
Other plasma cell disorder (PCD)  

 
 

7  Specify other preceding/concurrent disorder:

       

 
 
8  Date of diagnosis of preceding/concurrent disorder: __ __ __ __ - __ __- __ __  

 

Report values prior to first treatment for plasma cell disorder. 
 

9  WBC

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
10     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

11  Hemoglobin

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
12     

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 
 

13  Platelets

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
14     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

15  Absolute number of plasma cells in blood

    (For PCL only) 

 nmlkji
Known  

 nmlkji
Unknown  

  
 
16     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

17  Plasma cells in blood

    (For PCL only)  

 nmlkji
Known  

 nmlkji
Unknown  

 
 
18     % 

  Laboratory Studies at Diagnosis Questions: 9 - 118

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 23



 
 

19  Serum albumin

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
20     

 

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

21  Serum calcium

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
22     

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 nmlkji
mEq/L  

 
 

23  Serum creatinine

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
24     

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 nmlkji
µmol/L  

  
 
25  Upper limit of normal for serum creatinine:    

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 nmlkji
µmol/L  

 
 

26  LDH

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
27     

 

 nmlkji
U/L  

 nmlkji
µkat/L  

  
 
28  Upper limit of normal for LDH:    

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 
 

29  Serum β2 microglobulin

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
30     

 

 nmlkji
μg/dL  

 nmlkji
mg/L  

 nmlkji
nmol/L  

 
31  What was the Durie-Salmon staging?

    
 nmlkji

Stage 

I  

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma only;  low M-
component production rates IgG < 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4g/24h)   

 nmlkji
Stage II  (Fitting neither Stage I or Stage III) 

 nmlkji
Stage 

III  

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates IgG >7g/dL, IgA 

> 5g/dL; Bence Jones protein >12g/24h)  

 nmlkji
Unknown  

 
 

32  What was the Durie-Salmon sub classification?

    
 nmlkji

A  - relatively normal renal function (serum creatinine < 2.0 mg/dL) 

 nmlkji
B  - abnormal renal function (serum creatinine ≥ 2.0 mg/dL) 

 
 

33  Immunochemical type

    
 nmlkji

secretory  
 nmlkji

non-secretory  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 23



 

Specify paraproteins present:  
 

34  Serum heavy chain

    
 nmlkji

IgG  

 nmlkji
IgA  

 nmlkji
IgM  

 nmlkji
IgD  

 nmlkji
IgE  

 nmlkji
Biclonal  

 nmlkji
Not applicable (light chain only disease)  

 
 
35  Specify biclonal heavy chains:    

 
 

36  Serum light chain

    
 nmlkji

kappa  
 nmlkji

lambda  

 
 

37  Urine heavy chain

    
 nmlkji

IgG  

 nmlkji
IgA  

 nmlkji
IgM  

 nmlkji
IgD  

 nmlkji
IgE  

 nmlkji
Biclonal  

 nmlkji
Not applicable (light chain only disease)  

 
 
38  Specify biclonal heavy chains:    

 
 

39  Urine light chain

    
 nmlkji

kappa  
 nmlkji

lambda  

 
 

40  Serum monoclonal protein (M-spike): (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
41     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

42  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
43     mg/24 hours 

 
 

44  Total urinary protein excretion

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
45     g/24 hours 

 
 

46  24-hour creatinine clearance

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
47     ml/minute 

 
 

48  Serum free light chains — κ (kappa)

    
 nmlkji

Known  
 nmlkji

Unknown  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 23



  
 
49     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
50  Upper limit of normal for κ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

51  Serum free light chains — λ (lambda)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
52     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
53  Upper limit of normal for λ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 

Specify the following serum quantitative immunoglobulins (measured prior to any disease treatment): 
 

54  IgG

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
55     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
56  Upper limit of normal for IgG:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

57  IgA

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
58     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
59  Upper limit of normal for IgA:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

60  IgM

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
61     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
62  Upper limit of normal for IgM:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

63  IgD

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
64     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
65  Upper limit of normal for IgD:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

66  IgE

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
67     IU/mL 

 
 
68  Upper limit of normal for IgE:    IU/mL 

 
 

69  Plasma cells in bone marrow aspirate

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
70     % 

 
 

71  Plasma cells in bone marrow biopsy

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
72     % 

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 23



 
 

73  Were conventional cytogenetics tested?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

74  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

 

Specify cytogenetic abnormalities identified via conventional cytogenetics at diagnosis: 

Trisomy 

 
75  +3

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  +5

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  +7

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  +9

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  +11

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  +15

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  +19

    
 nmlkji

yes  
 nmlkji

no  

 

Translocation 
 

82  t(4;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  t(6;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  t(11;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  t(14;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  t(14;20)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

87  del(13q) / 13q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  del (17p) / 17p-

    
 nmlkji

yes  
 nmlkji

no  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 23



 

Other 
 

89  Hyperdiploid (>50)

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  Hypodiploid (<46)

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  Any abnormality at 1q

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Any abnormality at 1p

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Specify other abnormality:

       

 
 

95  Was documentation submitted to the CIBMTR?

    (e.g. cytogenetic report)  

 nmlkji
yes  

 nmlkji
no  

 
 

96  Were cytogenetics tested via FISH?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

97  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No abnormalities  

 

Specify cytogenetic abnormalities identified via FISH at diagnosis: 

Trisomy 

 
98  +3

    
 nmlkji

yes  
 nmlkji

no  

 
 

99  +5

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  +7

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  +9

    
 nmlkji

yes  
 nmlkji

no  

 
 

102  +11

    
 nmlkji

yes  
 nmlkji

no  

 
 

103  +15

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  +19

    
 nmlkji

yes  
 nmlkji

no  

 

Translocation 
 

105  t(4;14)

    
 nmlkji

yes  
 nmlkji

no  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 23



 
 

106  t(6;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

107  t(11;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  t(14;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

109  t(14;20)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

110  del(13q) / 13q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  del (17p) / 17p-

    
 nmlkji

yes  
 nmlkji

no  

 

Other 
 

112  Any abnormality at 1q

    
 nmlkji

yes  
 nmlkji

no  

 
 

113  Any abnormality at 1p

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 
115  Specify other abnormality:    

 
 

116  Was documentation submitted to the CIBMTR?

    (e.g. FISH report)  

 nmlkji
yes  

 nmlkji
no  

 
 

117  Was a gene expression profile performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

118  Were results considered high risk myeloma?

    
 nmlkji

yes  
 nmlkji

no  

 

Questions 119 – 187 are for amyloid patients only.  If diagnosis was other than amyloidosis (question 1), or there is no evidence or history of it (question 6), skip to question 
188. 

Specify organ involvement prior to any treatment:  
 

119  Was an abdominal fat aspirate performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Specify the aspirate results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 

Renal Involvement 
 

121  Was a renal biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

  Amyloidosis Organ Involvement at Diagnosis Questions: 119 - 187

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 23



 
 

122  Specify the renal biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 

Cardiac Involvement 
 

123  Was a cardiographic imaging procedure performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

124  Was a cardiac MRI done?

    
 nmlkji

yes  
 nmlkji

no  

 
 

125  Specify cardiac MRI results

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

126  Was the left ventricular ejection fraction measured?

    
 nmlkji

yes  
 nmlkji

no  

 
 
127  Specify the left ventricular ejection fraction:    % 

 
 

128  Specify the method used to determine the left ventricular ejection fraction

    
 nmlkji

Echocardiogram  

 nmlkji
Multiple gated acquisition (MUGA) scan  

 nmlkji
Cardiac MRI  

 nmlkji
Unknown  

 
 

129  Was diastolic dysfunction present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

130  Specify the interventricular septal wall thickness measured by echocardiogram

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
131     m m 

 
 

132  Was a cardiac biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

133  Specify the cardiac biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 
 

134  Were any serum cardiac biomarkers assessed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the cardiac biomarkers assessed: 
 

135  Brain natriuretic peptide (BNP)

    
 nmlkji

yes  
 nmlkji

no  

 
 
136  Specify the BNP level:    pg/mL 

 
 
137  Upper limit of normal for BNP:    pg/mL 

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 23



 
 

138  N-terminal prohormone brain natriuretic peptide (NT-proBNP)

    
 nmlkji

yes  
 nmlkji

no  

 
 
139  Specify the NT-proBNP level:    pg/mL 

 
 
140  Upper limit of normal for NT-proBNP:    pg/mL 

 
 

141  Troponin I

    
 nmlkji

yes  
 nmlkji

no  

 
 
142  Specify the troponin I level:    µg/L 

 
 
143  Upper limit of normal for troponin I:    µg/L 

 
 

144  Troponin T

    
 nmlkji

yes  
 nmlkji

no  

 
 
145  Specify the troponin T level:    µg/L 

 
 
146  Upper limit of normal for troponin T:    µg/L 

 
 

147  High sensitivity troponin T

    
 nmlkji

yes  
 nmlkji

no  

 
 
148  Specify the high sensitivity troponin T level:    µg/L 

 
 
149  Upper limit of normal for high sensitivity troponin T:    µg/L 

 
 

150  Specify the recipient's New York Heart Association functional classification of heart failure

    (Symptoms may include dyspnea, chest pain, fatigue, and palpitations; activity level should be assessed with consideration for patient's age-group) 

 nmlkji
Class I  – Able to perform ordinary activities without symptoms; no limitation of physical activity 

 nmlkji
Class II  – Ordinary physical activity produces symptoms; slight limitation of physical activity 

 nmlkji
Class III  – Less-than-ordinary physical activity produces symptoms; moderate limitation of physical activity 

 nmlkji
Class IV  – Symptoms present even at rest; severe limitation of physical activity 

 nmlkji
Unknown  

 

Gastrointestinal Involvement 
 

151  Was there clinical suspicion of gastrointestinal (GI) involvement?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the site(s) of GI involvement: 
 

152  Upper GI tract

    
 nmlkji

yes  
 nmlkji

no  

 
 

153  Lower GI tract

    
 nmlkji

yes  
 nmlkji

no  

 
 

154  Was a gastrointestinal biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify site(s) of GI biopsy: 
 

155  Rectal

    
 nmlkji

yes  
 nmlkji

no  

 
 

156  Specify the rectal biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 23



 
 

157  Other site

    
 nmlkji

yes  
 nmlkji

no  

 
 
158  Specify other GI biopsy site:    

 
 

159  Specify the biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 

Hepatic Involvement 
 

160  Was hepatomegaly present on radiographic imaging (liver span > 15 cm) or on examination (liver edge palpable >3 cm below right costal margin)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

161  Specify the level of serum alkaline phosphatase

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
162     

 

 nmlkji
IU/L  

 nmlkji
µkat/L  

  
 
163  Upper limit of normal for serum alkaline phosphatase :    

 

 nmlkji
IU/L  

 nmlkji
µkat/L  

 
 

164  Was a liver biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

165  Specify the liver biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 

Peripheral Neuropathy 
 

166  Was a sensory / motor exam performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

167  Specify the exam results

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

168  Was a nerve biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify site(s) of nerve biopsy: 
 

169  Sural

    
 nmlkji

yes  
 nmlkji

no  

 
 

170  Specify the sural nerve biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 
 

171  Other site

    
 nmlkji

yes  
 nmlkji

no  

  Other Nerve Biopsy Site (1) Questions: 172 - 173 

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 23



 
 
172  Specify other nerve biopsy site:    

 
 

173  Specify other nerve biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 
 

174  Did the recipient display any other evidence of peripheral nerve involvement for amyloidosis?

    
 nmlkji

yes  
 nmlkji

no  

 
 
175  Specify other evidence:    

 

Autonomic Neuropathy 
 

176  Did the recipient display symptomatic orthostatic hypotension (not attributable to medications or volume depletion)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

177  Did the recipient display any other evidence of autonomic neuropathy involvement (e.g. pseudo-obstruction or intractable diarrhea)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
178  Specify other evidence:    

 

Other Site(s) 
 

179  Did the recipient display any other clinical organ involvement?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the evidence of other organ involvement: 
 

180  Arthropathy

    
 nmlkji

yes  
 nmlkji

no  

 
 

181  Lung

    
 nmlkji

yes  
 nmlkji

no  

 
 

182  Soft tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 

183  Tongue (macroglossia)

    
 nmlkji

yes  
 nmlkji

no  

 
 

184  Other organ involvement

    
 nmlkji

yes  
 nmlkji

no  

 
 
185  Specify other organ:    

 
 

186  Was a biopsy performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

187  Specify the biopsy results

    
 nmlkji

Positive  (for amyloid involvement) 

 nmlkji
Negative  

 nmlkji
Unknown  

 
 

188  Was therapy given?

    
 nmlkji

yes  
 nmlkji

no  

  Pre-HCT Therapy Questions: 188 - 232

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 23



 
 

189  Systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 

190  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
191  Date started: __ __ __ __ - __ __- __ __  

 
 

192  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
193  Date stopped: __ __ __ __ - __ __- __ __  

 
 

194  Number of cycles

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
195  Number of cycles:    

 
 

196  VCD (Bortezomib (Velcade), cyclophosphamide, dexamethasone)

    
 nmlkji

yes  
 nmlkji

no  

 
 

197  RVD/VRD (Bortezomib (Velcade), dexamethasone, Lenalidomide (Revlimid))

    
 nmlkji

yes  
 nmlkji

no  

 
 

198  DVD/VDD (Bortezomib (Velcade), dexamethasone, liposomal doxorubicin (Doxil))

    
 nmlkji

yes  
 nmlkji

no  

 
 

199  RD (Dexamethasone, Lenalidomide (Revlimid))

    
 nmlkji

yes  
 nmlkji

no  

 
 

200  Bendamustine

    
 nmlkji

yes  
 nmlkji

no  

 
 

201  Bortezomib (Velcade)

    
 nmlkji

yes  
 nmlkji

no  

 
 

202  Carfilzomib

    
 nmlkji

yes  
 nmlkji

no  

 
 

203  Carmustine (BCNU, Gliadel)

    
 nmlkji

yes  
 nmlkji

no  

 
 

204  Cisplatin (Platinol, CDDP)

    
 nmlkji

yes  
 nmlkji

no  

 
 

205  Clarithromycin (Biaxin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

206  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 
 

207  Cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 
 

208  Cytarabine (Ara-C)

    
 nmlkji

yes  
 nmlkji

no  

 
 

209  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

  Line of Therapy (1) Questions: 189 - 232 

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 13 / 23



 
 

210  Doxorubicin liposomal (Doxil)

    
 nmlkji

yes  
 nmlkji

no  

 
 

211  Elotuzumab

    
 nmlkji

yes  
 nmlkji

no  

 
 

212  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

213  Idarubicin (Idamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

214  Interferon-α (Intron, Roferon) (includes PEG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

215  Lenalidomide (Revlimid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

216  Melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 
 

217  MLN 9708

    
 nmlkji

yes  
 nmlkji

no  

 
 

218  Pomalidomide

    
 nmlkji

yes  
 nmlkji

no  

 
 

219  Thalidomide (Thalomid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

220  Vorinostat

    
 nmlkji

yes  
 nmlkji

no  

 
 

221  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
222  Specify other systemic therapy:    

 
 

223  Was this line of therapy given for stem cell mobilization (priming)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

224  Radiation therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 

225  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
226  Date started: __ __ __ __ - __ __- __ __  

 
 

227  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
228  Date stopped: __ __ __ __ - __ __- __ __  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 14 / 23



 
229  Best response to line of therapy

    
 nmlkji

Stringent 

complete 

remission 

(sCR)  

— CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or 
immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ 
ratio. An abnormal Κ/λ ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal 
ratio reflecting the presence of an abnormal clone is Κ/λ of > 4:1 or < 1:2.)  sCR requires two consecutive assessments made at any time before the 
institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic 

studies are not required to satisfy sCR requirements.   

 nmlkji
Complete 

remission 

(CR)  

— negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone 
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the 
institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic 

studies are not required to satisfy CR requirements.   

 nmlkji
Near complete 

remission 

(nCR)  

— serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); ≤ 5% plasma cells in 
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of 
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.  

 nmlkji
Very good partial 

remission 

(VGPR)  

— serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein 
level < 100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known 
evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR 

requirements.   

 nmlkji
Partial 

remission 

(PR)  

≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M-protein are 
unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL.   Urine M-protein ≥ 200 mg/24 hours • serum free light chain 
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and 
uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay 

is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage 
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.  PR 
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone 

lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements.   

 nmlkji
Stable 

disease (SD)  

— not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new 
therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to 

satisfy SD requirements.  

 nmlkji
Progressive 

disease (PD)  

— requires any one or more of the following:  Increase of ≥ 25% from the lowest value achieved in:  serum M-component with an absolute increase ≥ 
0.5 g/dL (for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL); 
and/or urine M-component with an absolute increase ≥ 200 mg.24 hours; and/or for recipients without measurable serum and urine M-protein levels: 
the difference between involved and uninvolved free light chain levels with an absolute increase > 10 mg/dL; and/or bone marrow plasma cell 

percentage with absolute percentage ≥ 10% (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse); and/or definite development of 
new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. 
Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative 

disorder PD requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new 

therapy.  

 nmlkji
Relapse from CR 

(Rel) (untreated)  

— requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis development of ≥ 5% 
plasma cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of 

progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia)  Rel requires two consecutive assessments made at any time before 
classification as relapse, and/or the institution of any new therapy.  

 nmlkji
Unknown  

 nmlkji
Not applicable  (Amyloidosis with no evidence of myeloma) 

 
 
230  Date assessed: __ __ __ __ - __ __- __ __  

 
 

231  Did disease relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 
232  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 
 

233  Absolute number of plasma cells in blood

    (For PCL only)  

 nmlkji
Known  

 nmlkji
Unknown  

  
 
234     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

  Laboratory Studies at Last Evaluation Prior to Start of Preparative Regimen(Conditioning) Questions: 233 - 325

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 15 / 23



 
 

235  Plasma cells in blood

    (For PCL only)  

 nmlkji
Known  

 nmlkji
Unknown  

 
 
236     % 

 
 

237  Serum albumin

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
238     

 

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

239  Serum calcium

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
240     

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 nmlkji
mEq/L  

 
 

241  Serum β2 microglobulin

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
242     

 

 nmlkji
μg/dL  

 nmlkji
mg/L  

 nmlkji
nmol/L  

 
 

243  Serum monoclonal protein (M-spike): (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
244     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

245  Serum immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 

246  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

 

Specify bands present: 
 

247  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

248  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

249  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
250     mg/24 hours 

 
 

251  Urinary immunofixation

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 

252  Specify monoclonal immunoglobulin result

    
 nmlkji

Present  
 nmlkji

Absent  

 

Specify bands present: 
 

253  Original monoclonal bands

    
 nmlkji

yes  
 nmlkji

no  

 
 

254  New monoclonal (or oligoclonal) bands

    
 nmlkji

yes  
 nmlkji

no  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 16 / 23



 
 

255  Total urinary protein excretion

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
256     g/24 hours 

 
 

257  24-hour creatinine clearance

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
258     ml/minute 

 
 

259  Serum free light chains — κ (kappa)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
260     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
261  Upper limit of normal for κ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 
 

262  Serum free light chains — λ (lambda)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
263     

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

  
 
264  Upper limit of normal for λ free light chain:    

 

 nmlkji
mg/dL  

 nmlkji
mg/L  

 

Specify the following serum quantitative immunoglobulins: 
 

265  IgG

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
266     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
267  Upper limit of normal for IgG:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

268  IgA

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
269     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
270  Upper limit of normal for IgA:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

271  IgM

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
272     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
273  Upper limit of normal for IgM:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

274  IgD

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
275     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  
 
276  Upper limit of normal for IgD:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

277  IgE

    
 nmlkji

Known  
 nmlkji

Unknown  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 17 / 23



 
 
278     IU/mL 

 
 
279  Upper limit of normal for IgE:    IU/mL 

 
 

280  Plasma cells in bone marrow aspirate

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
281     % 

 
 

282  Plasma cells in bone marrow biopsy

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
283     % 

 
 

284  Were conventional cytogenetics tested?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

285  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

 

Specify cytogenetic abnormalities identified via conventional cytogenetics at last evaluation prior to the start of the preparative regimen: 

Trisomy 

 
286  +3

    
 nmlkji

yes  
 nmlkji

no  

 
 

287  +5

    
 nmlkji

yes  
 nmlkji

no  

 
 

288  +7

    
 nmlkji

yes  
 nmlkji

no  

 
 

289  +9

    
 nmlkji

yes  
 nmlkji

no  

 
 

290  +11

    
 nmlkji

yes  
 nmlkji

no  

 
 

291  +15

    
 nmlkji

yes  
 nmlkji

no  

 
 

292  +19

    
 nmlkji

yes  
 nmlkji

no  

 

Translocation 
 

293  t(4;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

294  t(6;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

295  t(11;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

296  t(14;16)

    
 nmlkji

yes  
 nmlkji

no  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 18 / 23



 
 

297  t(14;20)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

298  del(13q) / 13q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

299  del (17p) / 17p-

    
 nmlkji

yes  
 nmlkji

no  

 

Other 
 

300  Hyperdiploid (>50)

    
 nmlkji

yes  
 nmlkji

no  

 
 

301  Hypodiploid (<46)

    
 nmlkji

yes  
 nmlkji

no  

 
 

302  Any abnormality at 1q

    
 nmlkji

yes  
 nmlkji

no  

 
 

303  Any abnormality at 1p

    
 nmlkji

yes  
 nmlkji

no  

 
 

304  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 
305  Specify other abnormality:    

 
 

306  Were cytogenetics tested via FISH?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

307  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No abnormalities  

 

Specify cytogenetic abnormalities identified via FISH at last evaluation prior to the start of the preparative regimen: 

Trisomy 

 
308  +3

    
 nmlkji

yes  
 nmlkji

no  

 
 

309  +5

    
 nmlkji

yes  
 nmlkji

no  

 
 

310  +7

    
 nmlkji

yes  
 nmlkji

no  

 
 

311  +9

    
 nmlkji

yes  
 nmlkji

no  

 
 

312  +11

    
 nmlkji

yes  
 nmlkji

no  

 
 

313  +15

    
 nmlkji

yes  
 nmlkji

no  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 19 / 23



 
 

314  +19

    
 nmlkji

yes  
 nmlkji

no  

 

Translocation 
 

315  t(4;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

316  t(6;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

317  t(11;14)

    
 nmlkji

yes  
 nmlkji

no  

 
 

318  t(14;16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

319  t(14;20)

    
 nmlkji

yes  
 nmlkji

no  

 

Deletion 
 

320  del(13q) / 13q-

    
 nmlkji

yes  
 nmlkji

no  

 
 

321  del (17p) / 17p-

    
 nmlkji

yes  
 nmlkji

no  

 

Other 
 

322  Any abnormality at 1q

    
 nmlkji

yes  
 nmlkji

no  

 
 

323  Any abnormality at 1p

    
 nmlkji

yes  
 nmlkji

no  

 
 

324  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 
325  Specify other abnormality:    

 

Complete questions 326 – 362 are for amyloid patients only.  If diagnosis was other than amyloidosis (question 1), or there is no evidence or history of it (question 6), skip to 
question 363. 

Specify organ involvement prior to any treatment: 

Cardiac Involvement 

 
326  Was a cardiographic imaging procedure performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

327  Was a cardiac MRI done?

    
 nmlkji

yes  
 nmlkji

no  

 
 

328  Specify cardiac MRI results

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

329  Was the left ventricular ejection fraction measured?

    
 nmlkji

yes  
 nmlkji

no  

 
 
330  Specify the left ventricular ejection fraction:    % 

  Amyloidosis Organ Involvement at Last Evaluation Prior to Start of Preparative Regimen(Conditioning)Questions: 326 - 362

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 20 / 23



 
 

331  Specify the method used to determine the left ventricular ejection fraction

    
 nmlkji

Echocardiogram  

 nmlkji
Multiple gated acquisition (MUGA) scan  

 nmlkji
Cardiac MRI  

 nmlkji
Unknown  

 
 

332  Was diastolic dysfunction present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

333  Specify the interventricular septal wall thickness measured by echocardiogram

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
334     m m 

 
 

335  Were any serum cardiac biomarkers assessed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the cardiac biomarkers assessed: 
 

336  Brain natriuretic peptide (BNP)

    
 nmlkji

yes  
 nmlkji

no  

 
 
337  Specify the BNP level:    pg/mL 

 
 
338  Upper limit of normal for BNP:    pg/mL 

 
 

339  N-terminal prohormone brain natriuretic peptide (NT-proBNP)

    
 nmlkji

yes  
 nmlkji

no  

 
 
340  Specify the NT-proBNP level:    pg/mL 

 
 
341  Upper limit of normal for NT-proBNP:    pg/mL 

 
 

342  Troponin I

    
 nmlkji

yes  
 nmlkji

no  

 
 
343  Specify the troponin I level:    µg/L 

 
 
344  Upper limit of normal for troponin I:    µg/L 

 
 

345  Troponin T

    
 nmlkji

yes  
 nmlkji

no  

 
 
346  Specify the troponin T level:    µg/L 

 
 
347  Upper limit of normal for troponin T:    µg/L 

 
 

348  High sensitivity troponin T

    
 nmlkji

yes  
 nmlkji

no  

 
 
349  Specify the high sensitivity troponin T level:    µg/L 

 
 
350  Upper limit of normal for high sensitivity troponin T:    µg/L 

 
 

351  Specify the recipient's New York Heart Association functional classification of heart failure

    (Symptoms may include dyspnea, chest pain, fatigue, and palpitations; activity level should be assessed with consideration for patient's age-group) 

 nmlkji
Class I  – Able to perform ordinary activities without symptoms; no limitation of physical activity 

 nmlkji
Class II  – Ordinary physical activity produces symptoms; slight limitation of physical activity 

 nmlkji
Class III  – Less-than-ordinary physical activity produces symptoms; moderate limitation of physical activity 

 nmlkji
Class IV  – Symptoms present even at rest; severe limitation of physical activity 

 nmlkji
Unknown  

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 21 / 23



 

Hepatic Involvement 
 

352  Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

353  Specify the level of serum alkaline phosphatase

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
354     

 

 nmlkji
IU/L  

 nmlkji
µkat/L  

  
 
355  Upper limit of normal for serum alkaline phosphatase :    

 

 nmlkji
IU/L  

 nmlkji
µkat/L  

 

Peripheral Neuropathy 
 

356  Was a sensory / motor exam performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

357  Specify the exam results

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

358  Did the recipient display any new evidence of peripheral nerve involvement with amyloidosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
359  Specify other evidence:    

 

Autonomic Neuropathy 
 

360  Did the recipient display symptomatic orthostatic hypotension (not attributable to medications or volume depletion)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

361  Did the recipient display any other evidence of autonomic neuropathy involvement (e.g. pseudo-obstruction or intractable diarrhea)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
362  Specify other evidence:    

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 22 / 23



 
363  What was the disease status?

    (Report the most recent disease assessment prior to the preparative regimen.)   

 nmlkji
Stringent 

complete 

remission 

(sCR)  

— CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence 
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by 
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an 

abnormal clone is Κ/λ of > 4:1 or < 1:2.)  sCR requires two consecutive assessments made at any time before the institution of any new therapy, and no 
known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR 

requirements.   

 nmlkji
Complete 

remission 

(CR)  

— negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone marrow 
(confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution of any new 
therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy 

CR requirements.   

 nmlkji
Near complete 

remission (nCR)  

— serum & urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); ≤ 5% plasma cells in bone 
marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of progressive or 
new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements.  

 nmlkji
Very good partial 

remission 

(VGPR)  

— serum and urine M-protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein and urine M-protein level < 
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of 
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.   

 nmlkji
Partial 

remission 

(PR)  

— ≥ 50% reduction in serum M-protein, and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M-protein are 
unmeasurable (i.e., do not meet any of the following criteria: • serum M-protein ≥ 1 g/dL.   Urine M-protein ≥ 200 mg/24 hours • serum free light chain assay 
shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and uninvolved free 
light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, 

a ≥ 50% reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 30%. In addition to the 
above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.  PR requires two consecutive 
assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies 

were performed; radiographic studies are not required to satisfy PR requirements.   

 nmlkji
Stable 

disease (SD)  

— not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy, 
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD 

requirements.  

 nmlkji
Progressive 

disease (PD)  

— requires any one or more of the following:  Increase of ≥ 25% from the lowest value achieved in:  serum M-component with an absolute increase ≥ 0.5 g/dL 
(for progressive disease, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M-component is ≥ 5 g/dL); and/or urine M-
component with an absolute increase ≥ 200 mg.24 hours; and/or for recipients without measurable serum and urine M-protein levels: the difference between 
involved and uninvolved free light chain levels with an absolute increase > 10 mg/dL; and/or bone marrow plasma cell percentage with absolute percentage ≥ 
10% (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse); and/or definite development of new bone lesions or soft tissue 

plasmacytomas, or definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum 
calcium > 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder PD requires two consecutive assessments made at 

any time before classification as disease progression, and/or the institution of any new therapy.  

 nmlkji
Relapse from CR 

(Rel) (untreated)  

— requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis development of ≥ 5% plasma 
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g., 

new plasmacytoma, lytic bone lesion, hypercalcemia)  Rel requires two consecutive assessments made at any time before classification as relapse, 
and/or the institution of any new therapy.  

 nmlkji
Unknown  

 nmlkji
Not applicable  

(Amyloidosis with no evidence of myeloma) 

 
 
364  Date assessed: __ __ __ __ - __ __- __ __  

 
 
First Name:    

 
 
Last Name:    

 
 
E-mail address:    

 
 
Date: __ __ __ __ - __ __- __ __  

  Disease Status at the Last Evaluation Prior to Start of Preparative Regimen(Conditioning) Questions: 363 - 364

Form 2016 R3.0: Plasma Cell Disorders Pre-HCT Data  
Center:  CRID: 

CIBMTR Form 2016 revision 3.0 
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 23 / 23